Biotech | August 02, 2021
Windlas Biotech opens for subscription this week
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Turnover of API division of ISLL stood at Rs 856.58 crore
Price band in the range of Rs 933 to Rs 954
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
The company confirms an upward revision to its 2021 Outlook, reflecting the expectation to achieve mid-teens CER sales growth
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The company has already embarked upon significant expansion in Turkey
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Subscribe To Our Newsletter & Stay Updated
